FAQs
Frequently Asked Questions
General
Can I use the LRC-TriCEPS technology to identify the mode of action of my ligand of interest?
Yes, we can identify target receptors or co-receptors and in some cases also part of a protein complex that binds to the ligand of interest and therefore help to identify the mode-of-action of a molecule.
Can the LRC-TriCEPS technology be used for target deconvolution studies?
Yes, we can identify the target of your drug on living cells.
I want to do cell-cell interaction studies. That means my ligand of interest is a membrane protein and I suspect that its target is also a cell membrane protein on another cell. Can you help?
Yes, we can use the extracellular domain of your ligand of interest with i.e. Fc-fused and identify the binding partner on another cell.
I have a ligand with a low affinity to its targets. What is the sensitivity of the LRC-TriCEPS technology?
This is different for each ligand-receptor pair. In one case, we identified targets that bind the ligand with 2.5microM binding affinity. Furthermore, we were able to identify a receptor that was expressed with less than 2000 molecules per cells with a ligand with less than 1microM binding affinity.
What type of information I will receive upon completion of the experiment?
Upon completion of the LRC-TriCEPS experiment, the following items will be provided to you.
1) A detailed report outlining
- a) experimental design and procedures
- b) results in a format of figures and tables
- c) information regarding identified candidates
- d) detailed discussion on the overview of the experiment
- e) Raw files of the LC-MS/MS runs (upon request).
2) An Excel list of membrane associated proteins identified during the LRC-TriCEPS experiment along with information regarding the differential abundance across tested conditions.
How long does an LRC-TriCEPS experiment take?
From the moment the TriCEPS coupled ligands can be added to the cells it takes 4-5weeks till the report is provided.
Can you guarantee the success of the LRC-TriCEPS experiment?
We can cover the technical risk. If the positive control (i.e. transferrin, anti-CD28 antibody, anti-EGFR antibody) does not lead to identification of the known targets, we repeat the experiment once for free.
Ligand
Can I adapt the LRC-TriCEPS experiment so that I have the optimal binding conditions for my ligand of interest?
To find the best condition we advise to use Flow-TriCEPS where you can visualize the binding of your ligand to the cells in flow cytometry (available as kit or service). It is advised to perform optimization experiments to find the best binding conditions and then use those conditions during receptor capture in the main LRC-TriCEPS experiment. Receptor capture during the standard LRC-TriCEPS workflow is performed at pH 6.5 for 90min at 4oC. During a Flow-TriCEPS experiment, the effect of at least three factors on ligand binding is evaluated: pH, time and temperature. Additional factors (such as presence of a co-factor) can be also investigated.
Is my ligand still functional active/ able to bind to its target when coupled to TriCEPS?
If you have a functional assay we advise to couple TriCEPS to your ligand of interest and test if it is still functionally active compared to not coupled-ligand. We provide the Flow-TriCEPS kit that contains a ylated TriCEPS version where you can couple six times 20microg of ligand and visualize if the coupling worked by dot blot.
Where does TriCEPS couple to the ligand of interest?
To all primary amines. In peptides and proteins mainly to the N-Term and the Lysines. If you have a small molecule you might need to produce a derivative that contains a primary amine.
I expect that my ligand binds to more than one target. Can the LRC-TriCEPS technology identify multiple targets?
Yes, targets and off-targets can be identified in the same experiment.
I expect that my ligand binds to a receptor that forms homo or heterodimers. Can the LRC-TriCEPS technology identify these receptors?
Yes, since the cells are still alive during ligand-target interaction and the targets are in their natural micro-environment receptors are able to form dimers.
In what kind of buffer should the ligand of interest be available for use in a LRC-TriCEPS experiment?
Best is HEPES pH 8.2 or PBS pH 7.4
Most important is that the buffer does not contain any primary amines. Therefore Tris-HCl cannot be used as a buffer for the ligands unless removed (i.e. dialysis).
Should the ligand be purified?
The use of a pure ligand depleted of unknown contaminants is highly recommended.
Can my ligand be bound in beads or plate?
No, the ligand cannot be immobilized.
My ligand has a tag. Is that a problem?
No, the existence of a tag does not pose a problem.
Cells
When you perform LRC-TriCEPS for target identification are cells alive?
Yes, the cells are alive under near physiological conditions.
Do you need to genetically manipulate the cells?
No genetic manipulation (eg. ectopic expression) is needed.
Can you work with stimulated cells (i.e. activated T-Cells)?
Yes, in fact we encourage to find the best growth condition for the cells of your interest.
I have developed a complex way of growing cells to respond to my ligand of interest. Can I perform an LRC-TriCEPS experiment?
When cell culturing is not easily transferable, Dualsystems provides the TriCEPS material and the customer performs ligand coupling, receptor capture and collection of cells. The frozen cell pellets are then shipped to Dualsystems for further processing.
I do not know which cell type / cell line expresses the unknown target(s) of my ligand. Can you help?
Yes, with the Flow-TriCEPS kit you can couple your ligand of interest to a TriCEPS Version that contains a . The can then be used in flow cytometry to visualize the binding of your ligand to the cells. You can use the system to screen different cell types/ cell lines for the expression of the unknown target(s).
How much material do I need from my ligand of interest to perform one LRC-TriCEPS experiment?
In average, you need 300microg for a standard experiment using protein/antibodies as ligand. In case you have limited amounts of ligand available, we could design a customized experiment for you and then 100microg might also be enough. For peptides and small molecules, drop us a line.
How many cells are needed for one LRC-TriCEPS experiment?
The exact number of cells needed for one LRC experiment depends on the cell line. As a rule of thumb, a cell pellet with a volume of 50-100 microl is needed per sample. For most adherent cell lines that corresponds to 10-20×10^6 cells per sample. In a typical LRC-TriCEPS experiment, at least two treatment arms are performed in parallel: one with the ligand of interest and a second with a control ligand (that is, a ligand with a known target). Both arms are performed in triplicates to allow statistical analysis therefore roughly 60-120×10^6 cells in total are required.
In the case of primary cells from humans or animals (i.e. primary T cells) where the number of cells may be a limiting factor, we recommend performing the treatment arms in singletons but analyzing at least 3 different donors.
Can I use primary cells (i.e.T-cells) for my LRC-TriCEPS experiment?
Yes, from one donor it is expected to receive enough cells to perform an experiment with the ligand of interest and one control. As the number of cells per T-cell donor is not very large, the experiment is performed in singletons and triplicates are performed on the level of LC-MS/MS measurements. We recommend to perform an experiment on at least 3 different donors to see donor to donor variation.
I have adherent cells, is it possible to perform an LRC-TriCEPS experiment?
Yes, you can either detach the cells by adding EDTA or scraping prior to treatment with TriCEPS coupled ligand. However, we advise to add the TriCEPS coupled ligands directly to the plate so that the expression pattern of the cells is not altered during detachment of cells.
On what type of cells can you perform an LRC-TriCEPS experiment to identify the targets?
Any cell type that has glycosylation machinery.
Experimental setup
Is there a benefit if I perform an experiment for my ligand of interest with more than one control?
Yes, in the LRC-TriCEPS technology we do relative quantification of the surface proteins. We always do a pairwise comparison (ligand of interest compared to control 1, ligand of interest compared to control 2 etc.) If more than one control is used better evaluation of data can be performed.
Is there a benefit if I perform an experiment for my ligand of interest on different cell types?
Yes, it is interesting to see whether your ligand binds to the same targets across cell lines or different ones depending on the cell type.
What is the concentration of the ligand used during a LRC-TriCEPS experiment?
During a typical LRC-TriCEPS experiment the ligand of interest is added to the cells during receptor capture at a concentration between 10-35microg/ml.
Why do I need a control?
In a typical LRC-TriCEPS experiment, at least two treatment arms are performed in parallel: one with the ligand of interest and a second with a control ligand (that is, a ligand with a known target). The first step of the LRC includes the conjugation of the two ligands to TriCEPS. The TriCEPS-ligand conjugates are then incubated with previously oxidized cells under near-physiological conditions. During this phase, transient and stable ligand-receptor interactions will result in covalent capture events between TRICEPS and nearby carbohydrates. After the receptor-capture reaction, the cells are lysed, proteins are isolated and processed for MS-based analysis. Upon identification, the relative abundance of cell surface proteins in the ligand samples are compared to those in the control sample using MS1-based label-free quantification. Randomly identified cell surface proteins are expected to have equal abundance in both samples, whereas the corresponding receptors are found enriched in the ligand sample.
Chemistry
How large is TriCEPS/ Hatric?
Ca. 1.2 kDa.
How stable is the interaction between the ligand and the target?
Transient and stable ligand-receptor interactions result in covalent capture events between TRICEPS and nearby carbohydrates.
Materials needed
What is the number of cells and the amount of ligand needed for an LRC-TriCEPS experiment?
300microg of ligand and ca. 60 Mio cells.
What is the number of cells needed for the pre-experiment using flow cytometry to identify the best binding conditions?
Normally ca. 5×10^6 cells are enough for a pretest.
Unknown target(s)
I have no expectation what the target of my ligand is. Can the LRC-TriCEPS technology still help to identify the unknown targets of my ligand?
Yes, we only need cells that express the unknown target. (see Flow-TriCEPS for cell type identification).
I suspect my ligand binds first an extracellular matrix protein that then binds to a protein to transduce the signal intracellularly. Can the LRC-TriCEPS technology still help to identify the unknown targets of my ligand?
Yes, we have shown that we also can identify co-receptors.
Are there any limitations concerning the targets that can be identified?
The target has to be a protein with at least one glycosylation site. It is expected that more than 90% of the cell membrane associated proteins are glycosylated.
How many target candidates are expected to be identified?
A candidate list of less than 5 is expected.
Do I need to artificially overexpress potential target proteins to be able to show the binding?
No, cells are not genetically manipulated.
Contact form
Please fill out all mandatory (*) fields.
Customers Testimonials – LRC-TriCEPS Service
Testimonials from our customers who have used the LRC-TriCEPS technology – in collaboration with Dualsystems Biotech AG.
OncoLille Cancer Institute
We aim to identify the ligand of a receptor, but due to the low affinity of the interaction other approaches that have been tried failed. Paul Helbling and the DualSystem team provided a great support and critical insights for performing the ligand identification using the LCR-TriCEPS technology. We found now a candidate ligand that we are currently validating with promising results. DualSystem team has been really professional and of great support in this process and we plan to work again with them in the future.
Best,
Silvia Gaggero, PhD
Mitra Lab, Inserm
OncoLille Cancer Institute
Lille, France
Best,
Silvia Gaggero, PhD
Mitra Lab, Inserm
OncoLille Cancer Institute
Lille, France
2024-06-06T12:25:14+00:00
https://www.dualsystems.com/testimonials/oncolille-cancer-institute/
AstraZeneca
We needed to identify the target of an antibody from a phenotypic screening approach using a difficult iPSC-derived cell line and reached-out to DualSystems and their LRC-TriCEPS technology after an earlier attempt at target deconvolution using an array of membrane targets had failed. The support I got from Paul Helbling and his team was great and as someone who was unfamiliar with the approach, I really appreciated the advice and guidance that I got. At the end of the process the top candidate from the analysis was confirmed as the target of the antibody – a brilliant result! Overall, a really positive experience and I would definitely recommend DualSystems.
James Dodgson
AstraZeneca
Cambridge, UK.
James Dodgson
AstraZeneca
Cambridge, UK.
2023-05-24T20:08:08+00:00
https://www.dualsystems.com/testimonials/astrazeneca/
UCF College of Medicine
“DualSystems LRC-TriCEPS platform helped us in the identification of a novel allergen receptor. This finding was central to our recently published work and funded grant! DualSystems was very helpful during the entire process, if you are considering using this platform, do not hesitate. The process is straightforward and the support is excellent!”
Justine Tigno-Aranjuez, Ph.D.
Assistant Professor of Medicine
UCF College of Medicine
Justine Tigno-Aranjuez, Ph.D.
Assistant Professor of Medicine
UCF College of Medicine
2023-03-16T06:40:12+00:00
https://www.dualsystems.com/testimonials/ucf-college-of-medicine/
Cohbar
DualSystems' LRC-TriCEPS platform was exactly what we needed to identify potential targets and guide us in mechanism of action studies for our peptide program. They helped us every step of the way -- from understanding their capabilities, to guiding study design, and supporting sample preparation. The report they delivered exceeded our expectations and truly stands out from data reports we've received from other companies. They were readily available to answer questions and discuss concerns or outcomes. We are very encouraged by the results and are currently following up on the targets identified. We highly recommend working with DualSystems and incorporating the LRC-TriCEPS platform into your program. We look forward to working with the DualSystems team again in the future.
Dr. Lindsay Stark
Drug Discovery Scientist at CohBar
Dr. Lindsay Stark
Drug Discovery Scientist at CohBar
2023-01-18T08:14:48+00:00
https://www.dualsystems.com/testimonials/cohbar/
Technical University of Munich
Technical University of Munich – Institute of Experimental Oncology and Therapy Research
Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest.
At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS.
Prof. Dr. rer. nat. Achim Krüger
Institute of Experimental Oncology and Therapy Research
Klinikum rechts der Isar, Technical University of Munich
Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest.
At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS.
Prof. Dr. rer. nat. Achim Krüger
Institute of Experimental Oncology and Therapy Research
Klinikum rechts der Isar, Technical University of Munich
2022-07-27T14:23:02+00:00
https://www.dualsystems.com/testimonials/technical-university-of-munich/
University of Miyazaki
We appreciate the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify a binding protein for our insulinotropic peptide
Hideyuki Sakoda, MD, PhD
Associate professor
Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.
Hideyuki Sakoda, MD, PhD
Associate professor
Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.
2022-04-19T11:45:22+00:00
https://www.dualsystems.com/testimonials/university-of-miyazaki/
Lund University Diabetes Centre
We wanted to use LRC-TriCEPS to characterise the mechanism of action of our ligand of interest. Not only were several candidate targets identified but we have successfully validated two of these receptors in insulin producing beta cells. DualSystems Biotech were very helpful and involved from study design, to experiments and reporting. Even after the initial report, DualSystems Biotech have answered follow up queries and provided assistance regarding publications. I highly recommend the LRC-TriCEPS technology and DualSystems Biotech and Paul Helbling and his team to work with.
Dr. Claire L. Lyons,
Associate Researcher
Unit of Medical Protein Science
Lund University Diabetes Centre
Sweden
Dr. Claire L. Lyons,
Associate Researcher
Unit of Medical Protein Science
Lund University Diabetes Centre
Sweden
2021-10-25T05:58:59+00:00
https://www.dualsystems.com/testimonials/lund-university-diabetes-centre/
Australian National University
“We had a challenging project where we aimed to discover the receptor of our ligand of interest in primary human cells. Dualsystems Biotech took the challenge and provided outstanding support throughout the entire process, from the experimental design to data analysis. Using their LRC-TriCEPS technology, we could identify a candidate receptor and additional downstream interacting partners that we have now validated. We look forward to new collaborations and discoveries with Dr Paul Helbling and his team”. – Prof Carola Vinuesa, ANU
The Australian National University
Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence
College of Health & Medicine
The Australian National University
The Australian National University
Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence
College of Health & Medicine
The Australian National University
2021-01-11T08:16:02+00:00
https://www.dualsystems.com/testimonials/australian-national-university/
Harvard Medical School, Brigham and Women’s Hospital
We used DualSystems to help identify a potential novel receptor for a ligand that despite being studied for decades had unclear catabolism mechanisms involving its receptor mediated uptake. The DualSystems team will walk you through the process, including early validation of your ligand being used for this technology, data collection and analysis, and provide an easy to follow report on the findings. For anyone interested in receptor-ligand interactions, DualSystems and the TriCEPS approach is worth strongly considering involving in your research program, as it can quickly help identify receptors that would have been very difficult to do so without.
Maximillian Rogers, PhD
Research Scientist
Harvard Medical School, Brigham and Women's Hospital
Department of Medicine, Cardiovascular Division
Boston, MA
Maximillian Rogers, PhD
Research Scientist
Harvard Medical School, Brigham and Women's Hospital
Department of Medicine, Cardiovascular Division
Boston, MA
2020-11-09T13:27:52+00:00
https://www.dualsystems.com/testimonials/harvard-medical-school-brigham-and-womens-hospital/
Center for Biomolecular & Cellular Structure, Institute for Basic Science
“It was my great pleasure to collaborate with Dualsystems Biotech. We have been tested various proteomic analysis to identify the specific receptor for our secreted ligand. But, only LRC-TriCEPS experiment successfully gave us a right answer, because this receptor and ligand interactions were indeed relatively weaker than other general receptor and ligand interactions. The team very kindly consulted the whole experimental steps from the experimental design to the final data analysis. We are now going to use TriCEPS again for several other secreted ligands with a great hope for discovery of new receptors. Best Regards, Ho Min Kim”
Associate Professor
Graduate School of Medical Science and Engineering, KAIST
Chief Investigator
Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS)
Associate Professor
Graduate School of Medical Science and Engineering, KAIST
Chief Investigator
Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS)
2020-08-12T13:02:47+00:00
https://www.dualsystems.com/testimonials/center-for-biomolecular-cellular-structure-institute-for-basic-science/
Department of Internal Medicine Erasmus MC
We were fortunate to partner with Dualsystems Biotech AG to discover cell-surface targets for the short-peptide ligand we had been working on for several years. We decided to try the LRC-TriCEPS approach to identify cell-surface binding partners for the ligand after several earlier aborted attempts using different techniques. Using LRC-TriCEPS we have identified targets that we have now been able to verify functionally and biochemically using other methods. It was a pleasure to work with Dr Paul Helbling and his team who were extremely helpful guiding us through the experimental process and assisting with analysis of the data. We were impressed by the quality of the data and the ease with which we were able to run the study.
Dr Patric Delhanty
Laboratory of Metabolism and Reproduction
Department of Internal Medicine
Erasmus MC
Rotterdam, The Netherlands
Dr Patric DelhantyLaboratory of Metabolism and Reproduction
Department of Internal Medicine
Erasmus MC
Rotterdam, The Netherlands
2020-04-28T11:54:52+00:00
https://www.dualsystems.com/testimonials/department-of-internal-medicine-erasmus-mc/
Seoul National University
"I have used many binding assays and was in the verge of giving up. Then I have contacted Dr. Paul Helbling and his group. The LRC-TriCEPS experiment was effective and let us go over the obstacle we had during the project. We look forward to using TriCEPS in the future".
Chung Hwan Cho, Ph. D. candidate
Environmental Health Microbiology Laboratory
Department of Environmental Public Health
Seoul National University
Chung Hwan Cho, Ph. D. candidate
Environmental Health Microbiology Laboratory
Department of Environmental Public Health
Seoul National University
2020-01-29T14:05:52+00:00
https://www.dualsystems.com/testimonials/seoul-national-university/
The University of Oklahoma – Health Sciences Center
I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped us develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed the interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.
Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
2019-07-02T04:38:05+00:00
https://www.dualsystems.com/testimonials/the-university-of-oklahoma-health-sciences-center/
CuroNZ Ltd
The team from DualSystems Biotech AG has been extremely helpful in delivering scientific advice for CuroNZ’s target identification journey. The quick turnaround time and the precision of NRP2945’s target identification in regard to the utilization of their TRICEPS technology impressed us very much. Meanwhile we could identify another NRP2945 receptor target that was identified by DualSystems as being recruited to the NRP2945-activated membrane receptor complex. An absolute pleasure to work with Paul Helbling’s team.
Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand
Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand
2019-02-20T12:18:04+00:00
https://www.dualsystems.com/testimonials/curonz-ltd/
University of Pittsburgh
It was a pleasure working with Paul Helbling and his team. I was impressed by their attention to detail, and optimization of all cell conditions to produce the most reliable possible results. They kept me informed at every stage of the process and shared data as soon as they were able to. Using their LRC-TriCEPS platform, we were able to follow leading candidates as binding partners for our cardiac targeting peptide and identified the most likely binding partner.
Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh
Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh
2018-11-15T19:35:14+00:00
https://www.dualsystems.com/testimonials/university-of-pittsburgh/
University of Oklahoma Health Sciences Center
I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped our lab develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed this interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.
Anne Kasus-Jacobi, PhD
Assistant Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
Anne Kasus-Jacobi, PhD
Assistant Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA
2018-04-23T11:45:16+00:00
https://www.dualsystems.com/testimonials/lrc-triceps/
Biomedical Research Institute
PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.
The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.
(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA
The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.
(Quim) Madrenas, MD, PhD, FCAHSChief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA
2018-04-19T11:18:18+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-8/
QIMR Berghofer Medical Research Institute
“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”
Anita Burgess | PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
Anita Burgess | PhDHepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
2017-12-12T13:21:33+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-7/
University of Miami, Miller School of Medicine
We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dr Karina GaloianResearch associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
2017-11-16T08:07:04+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-6/
Münster University Hospital (UKM)
"Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed."
Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
Dr. rer. nat. Martin HeroldWorking group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
2017-08-24T14:48:20+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-5/
University of Manitoba
"Every aspect of our experience with Dualsystems Biotech was outstanding. They provided excellent customer service and technical support throughout the entire process. Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research."
Sari S. Hannila, PhD
Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
Sari S. Hannila, PhDAssociate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
2017-06-12T10:05:43+00:00
https://www.dualsystems.com/testimonials/lrc-service/
The Rockefeller University
"We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question."
Manish Ponda, M.D., M.S.
Assistant Professor of Clinical Investigation
The Rockefeller University
Manish Ponda, M.D., M.S.Assistant Professor of Clinical Investigation
The Rockefeller University
2016-10-10T14:21:51+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-3/
Medizinische Hochschule Hannover
“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.”
Dr. rer. nat. Inga Sörensen-Zender
Postdoc
Medizinische Hochschule Hannover
Dr. rer. nat. Inga Sörensen-ZenderPostdoc
Medizinische Hochschule Hannover
2016-09-26T10:26:51+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-2/
East Tennessee State University
“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”
Jonathan M Peterson
Assistant Professor
East Tennessee State University
Jonathan M PetersonAssistant Professor
East Tennessee State University
2016-05-30T15:20:03+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service/
Igenica Biotherapeutics
«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»
Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics
Dr. Edward van der Horst,Senior Director, Preclinical Development
Igenica Biotherapeutics
2016-05-09T11:13:08+00:00
https://www.dualsystems.com/testimonials/lrc-triceps-service-4/
Centro de Estudos de Doenças Crónicas
New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »
Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »
Alisson M. Gontijo,Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
2015-02-24T07:32:40+00:00
https://www.dualsystems.com/testimonials/captirec-service-3/
Washington University School of Medicine
"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".
Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine
Fumihiko Urano, MD, PhDSamuel E. Schechter Professor of Medicine
Washington University School of Medicine
2015-02-17T14:30:12+00:00
https://www.dualsystems.com/testimonials/captirec-service-2/
University of California San Francisco
"We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor." 
De'Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)
De'Broski R. Herbert Ph.D.Assistant Professor in Residence
University of California San Francisco (UCSF)
2015-02-17T14:27:53+00:00
https://www.dualsystems.com/testimonials/captirec-service/
LRC-TriCEPS customers worldwide
Over 200 satisfied customers from 28 countries.
Social Media
